GlassScriptPhysician profile
Siting S S Chen
NPI 1689662587
$681.42
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.13 · 2020: $110 · 2022: $385 · 2023: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $167.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $150.41 | 2022-2023 | Opdualag |
| Astrazeneca Pharmaceuticals LP | $110.00 | 2020 | |
| Astellas Pharma US INC | $99.99 | 2022 | |
| Amgen INC. | $81.99 | 2022 | |
| Merck Sharp & Dohme LLC | $44.56 | 2023 | Keytruda, Reblozyl, Welireg |
| Novartis Pharmaceuticals Corporation | $39.37 | 2023 | |
| Eisai INC. | $31.47 | 2022 | |
| Alexion Pharmaceuticals, INC. | $30.16 | 2022 | |
| Janssen Biotech, INC. | $24.61 | 2023 | Darzalex, Imbruvica |
| Progenics Pharmaceuticals, INC. | $24.36 | 2023 | Pylarify |
| Agios Pharmaceuticals, INC. | $19.13 | 2019 | |
| Aveo Pharmaceuticals, INC. | $13.35 | 2023 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siting Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.